| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10484671 | Value in Health | 2013 | 14 Pages |
Abstract
In patients previously treated for chronic HCV genotype-1 infection, BOC was projected to increase quality-adjusted life-years and reduce the lifetime incidence of liver complications. In addition, BOC-based therapies were projected to be cost-effective in comparison with PR alone at commonly used willingness-to-pay thresholds.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jagpreet PhD, Shannon A. PhD, Cliff MD, PhD, Antoine C. PhD, Margaret MD, Bruce MD, Rafael MD, Elamin H. PhD,